NVDA vs PI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NVDA exhibits strong financial health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and solvency. While the current price of $182.08 is significantly above the Graham Number ($26.71) and the growth-based intrinsic value ($144.55), the stock is fundamentally undervalued relative to its growth, as evidenced by a PEG ratio of 0.72 and a highly attractive Forward P/E of 16.38. The company's elite profitability margins (55.6% profit margin) and minimal debt (0.07 D/E) provide a massive cushion for volatility. Despite bearish insider sentiment and short-term technical weakness, the long-term growth trajectory remains exceptionally strong.
Impinj, Inc. presents a precarious profile characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete lack of valuation support from traditional metrics. The company is trading at an extreme premium with a Price/Book of 15.95 and Price/Sales of 9.25, despite negative profit margins (-3.00%) and stagnant revenue growth of only 1.40% YoY. This fundamental disconnect is compounded by aggressive insider selling totaling over $106 million and a severe 6-month price decline of 45.1%. While analyst targets remain optimistic, the data suggests a significant valuation bubble relative to current operational performance.
Compare Another Pair
Related Comparisons
NVDA vs PI: Head-to-Head Comparison
This page compares NVIDIA Corporation (NVDA) and Impinj, Inc. (PI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.